Literature DB >> 1203845

Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung.

E W Barnes, A Farmer, W J Penhale, W J Irvine, P Roscoe, N W Horne.   

Abstract

The transformation of peripheral blood lymphocytes in response to PHA was studied in 37 newly presenting patients who were subsequently proven to have carcinoma of the lung. When compared with healthy age- and sex-matched normal controls, no differences were noted in the thymidine uptake of the unstimulated lymphocytes in culture or in the response to any of the three dose levels of PHA used. Neither the extent of the spread of the carcinoma nor the type of its histology showed any correlation with the PHA response, but the PHA response was significantly depressed within 14 days of death in 7 patients. No evidence for serum inhibitory factors was found.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203845     DOI: 10.1002/1097-0142(197507)36:1<187::aid-cncr2820360117>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer.

Authors:  T Toge; H Ikeda; N Senoo; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1976-12

2.  Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG.

Authors:  B H Stack; N McSwan; J M Stirling; D J Hole; D Parratt; W G Spilg; C R Gillis; I McHattie; A G Green; R G White; M A Turner
Journal:  Thorax       Date:  1979-02       Impact factor: 9.139

3.  Total T lymphocytes in primary bronchial carcinoma.

Authors:  H L Roberts; W T Donohoe; S Hewitt; D A Price Evans
Journal:  Thorax       Date:  1977-02       Impact factor: 9.139

Review 4.  Immunology of bronchial carcinoma.

Authors:  D A Evans
Journal:  Thorax       Date:  1976-10       Impact factor: 9.139

5.  Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma.

Authors:  A M Liberati; J G Voelkel; E C Borden; A S Coates; D L Citrin; G T Bryan
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma.

Authors:  J W Millar; P Roscoe; S J Pearce; S Ludgate; N W Horne
Journal:  Thorax       Date:  1982-01       Impact factor: 9.139

7.  Mycobacterial isolations in young adults with cystic fibrosis.

Authors:  M J Smith; J Efthimiou; M E Hodson; J C Batten
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

8.  Lymphocyte transformation in cancer patients: variation in results according to technique.

Authors:  G M Gyte; S M Watkins
Journal:  J Clin Pathol       Date:  1978-02       Impact factor: 3.411

9.  Value of lymphocyte reactivity induced by phytohemagglutinin in the treatment of malignant diseases.

Authors:  S Fujimoto; T Minami; B Itoh; H Ishigami; M Miyazaki
Journal:  Jpn J Surg       Date:  1977-03

10.  T- and B-cell responses in patients with malignant pleural effusions.

Authors:  A M Potrykus; G Steinmann; E Stein; R Mertelsmann
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.